Adam Siddiqui-Jain

发表

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

D. V. Von Hoff, Adam Siddiqui-Jain, J. Bliesath, 2012, Molecular Cancer Therapeutics.

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

R. Hannan, M. Bywater, E. Sanij, 2011, Cancer research.

Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription

D. Bearss, L. Hurley, Adam Siddiqui-Jain, 2002, Proceedings of the National Academy of Sciences of the United States of America.

The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4.

L. Hurley, Adam Siddiqui-Jain, Jeyaprakashnarayanan Seenisamy, 2004, Journal of the American Chemical Society.

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2010, Cancer research.

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.

Adam Siddiqui-Jain, Diwata Macalino, Nicole Streiner, 2011, Bioorganic & medicinal chemistry letters.

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Journal of medicinal chemistry.

Abstract 235: AXL inhibition leads to a reversal of a mesenchymal phenotype sensitizing cancer cells to targeted agents and immuno-oncology therapies

D. Bearss, Adam Siddiqui-Jain, S. Warner, 2016 .

Therapeutics , Targets , and Chemical Biology CX-4945 , an Orally Bioavailable Selective Inhibitor of Protein Kinase CK 2 , Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Brien, Adam Siddiqui-Jain, J. Bliesath, 2010 .

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Molecular and Cellular Biochemistry.

Preclinical Development CK 2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Ef fi cacy : Mechanistic Rationale for Drug Combination Therapy

D. V. Hoff, Adam Siddiqui-Jain, J. Bliesath, 2012 .

DNA structure: Visualizing the quadruplex.

L. Hurley, Adam Siddiqui-Jain, 2013, Nature chemistry.

Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure.

Vijay Gokhale, Kazuo Shin-Ya, Daekyu Sun, 2005, Journal of the American Chemical Society.

Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties.

Adam Siddiqui-Jain, Nicole Streiner, Caroline B. Ho, 2011, Bioorganic & medicinal chemistry letters.

Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.

Amy Lin, D. V. Von Hoff, Adam Siddiqui-Jain, 2009, Cancer research.

Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.

Marc D. H. Hansen, Adam Siddiqui-Jain, S. Herron, 2017, Bioorganic & medicinal chemistry letters.

Conformationally restricted analogues of psorospermin: design, synthesis, and bioactivity of natural-product-related bisfuranoxanthones.

L. Hurley, Adam Siddiqui-Jain, T. Dexheimer, 2005, Journal of medicinal chemistry.

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, Cancer letters.

Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.

Roberto Battistutta, L. Pinna, R. Battistutta, 2011, Biochemistry.

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Biochemical and biophysical research communications.

Combined venetoclax and alvocidib in acute myeloid leukemia

R. Mesa, D. Bearss, C. Shi, 2017, Oncotarget.

Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.

Adam Siddiqui-Jain, Diwata Macalino, Nicole Streiner, 2012, Bioorganic & medicinal chemistry letters.

Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element.

D. V. Von Hoff, Danzhou Yang, L. Hurley, 2006, Seminars in oncology.

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.

Adam Siddiqui-Jain, J. Bliesath, Diwata Macalino, 2012, ACS medicinal chemistry letters.

CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells

Adam Siddiqui-Jain, J. Bliesath, Nicole Streiner, 2010 .

Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.

Marc D. H. Hansen, D. Cescon, Adam Siddiqui-Jain, 2018, Bioorganic & medicinal chemistry letters.

Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib

D. Bearss, Adam Siddiqui-Jain, S. Warner, 2017 .

Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs.

Adam Siddiqui-Jain, Diwata Macalino, S. O'Brien, 2012, Bioorganic & medicinal chemistry letters.

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.

Adam Siddiqui-Jain, Diwata Macalino, Nicole Streiner, 2012, Bioorganic & medicinal chemistry letters.